Market Place
Sourcing Support
Celltrion to Present 7 Abstracts in IBD at Digestive Disease Week
21 Apr 2026 //
PR NEWSWIRE
New ECCO Data Show Subcutaneous SC) Infliximab (Remsima™ SC)
16 Feb 2026 //
BUSINESSWIRE
Celltrion To Present At 44th J.P. Morgan Healthcare Conference
06 Jan 2026 //
PR NEWSWIRE
Celltrion Shares Real-World Data On IV-To-SC Infliximab Switch
06 Oct 2025 //
PHARMAWEB
Celltrion Unit Pays $330 M for Eli Lilly Production Facility
23 Sep 2025 //
REUTERS
Celltrion Close to US Plant Purchase Amid Tariff Threats
30 Jul 2025 //
FIERCE PHARMA
Celltrion Opens UK Headquarters in Uxbridge
23 Jun 2025 //
CONTRACTPHARMA
Celltrion opens new UK headquarters in Uxbridge, UK
18 Jun 2025 //
BUSINESSWIRE
Celltrion to present six IBD abstracts at 2025 DDW
28 Apr 2025 //
PR NEWSWIRE
Celltrion Shares Drug Pipeline Vision At J.P. Morgan Conference
14 Jan 2025 //
PR NEWSWIRE
Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion
02 Jul 2024 //
BIOSPECTRUM ASIA
Celltrion showcases promising results in phase III study for CT-P47
13 Jun 2024 //
BUSINESSWIRE
ZYMFENTRA Demonstrates 2-Year Crohn`s, UC Efficacy, Safety Profile
21 May 2024 //
PR NEWSWIRE
Reality Star Backs Campaign On Condition Impacting Millions
18 May 2024 //
BUSINESSWIRE
Celltrion USA, Express Scripts Deal For ZYMFENTRA™ & Autoimmune Therapies
28 Apr 2024 //
PR NEWSWIRE
Health Canada Approves Remsima™ SC for the Treatment of IBD
18 Feb 2024 //
BUSINESSWIRE
Celltrion USA announces distribution and incorporation of YUFLYMA
26 Oct 2023 //
BUSINESSWIRE
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA
23 Oct 2023 //
BUSINESSWIRE
Celltrion USA has signed a contract with Ventegra® to add Yuflyma
05 Oct 2023 //
BUSINESSWIRE
Celltrion to Participate in the Morgan Stanley 21st Annual Global Conference
06 Sep 2023 //
BUSINESSWIRE
Celltrion campaign wants you to find `hidden characters` of IBD
19 May 2023 //
FIERCE PHARMA
Bora Pharma, Celltrion Partner to Expand OSD Capabilities in the APAC Market
06 Apr 2023 //
CONTRACT PHARMA
Baxter`s for-sale CMO attracts Thermo Fisher, Celltrion
22 Mar 2023 //
FIERCE PHARMA
Celltrion & LISCure announce collaboration for Parkinson`s disease
20 Feb 2023 //
PR NEWSWIRE
Celltrion and Rani Therapeutics Partner on Development of Antibody Treatment
09 Jan 2023 //
GLOBENEWSWIRE
Celltrion submits application for CT-P13 SC to FDA
22 Dec 2022 //
PHARMAFILE
Celltrion USA announces submission of the (BLA) novel sub formulation of CT-P13
22 Dec 2022 //
BUSINESSWIRE
Brand Institute Partners on Brand Name Dev for Approved Biologic Medication
19 Oct 2022 //
PRNEWSWIRE
Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma
28 Sep 2022 //
BUSINESSWIRE
Celltrion’s anticancer biosimilar Vegzelma authorized for sales in Japan
27 Sep 2022 //
KOREABIOMED
Abpro to Partnership with Celltrion for Development of a Antibody
22 Sep 2022 //
BUSINESSWIRE
Celltrion’s Vegzelma receives EC approval for cancer treatments
19 Aug 2022 //
PHARMACEUTICAL TECHNOLOGY
EC Approves Celltrion`s Vegzelma for the Treatment of Multiple Types of Cancer
18 Aug 2022 //
BUSINESSWIRE
Celltrion`s CT-P47 approved for Phase 3 trials in Poland
19 Jul 2022 //
KOREA DAILY
Celltrion Healthcare receives CHMP positive opinion for biosimilar bevacizumab, Vegzelma™ (CT-P16)
27 Jun 2022 //
PRESS RELEASE
Celltrion finishes global patent agreement for Avastin biosimilar CT-P16
20 May 2022 //
KOREABIOMED
Celltrion sends trial plans for global P3 study for Actemra biosimilar
17 May 2022 //
KOREABIOMED
High Infliximab Trough Levels Associated With Low Risk of Relapse on Infliximab
18 Feb 2022 //
BUSINESSWIRE
Celltrion seeks US FDA nod to initiate global phase III trial of regdanvimab
08 Feb 2022 //
PHARMABIZ
Celltrion Submits IND for Global Phase III Trial of Inhaled COVID-19 Ab Cocktail
06 Feb 2022 //
BUSINESSWIRE
Celltrion announces +ve results for cocktail therapy against Omicron variant
03 Jan 2022 //
BUSINESSWIRE
Celltrion`s COVID-19 candidate treatment shows safety in clinical trial
03 Jan 2022 //
KOREAHERALD
Celltrion`s new Humira biosimilar wins approval in Canada
31 Dec 2021 //
YNA
Celltrion`s CT-P17 gets the nod in Canada
29 Dec 2021 //
KOREAJOONGANGDAILY
Celltrion signs COVID-19 antibody therapy supply deals with Europe
30 Nov 2021 //
EXPRESS PHARMA
Celltrion accelerates devP of nebulised cocktail therapy CT-P63
29 Nov 2021 //
BUSINESSWIRE
CHMP recommends 11 new medicines for authorization, including two COVID-19 MAb
16 Nov 2021 //
RAPS
EC approves Celltrion’s COVID-19 mAb Regkirona
16 Nov 2021 //
PHARMATIMES
Celltrion’s Truxima posts 46 percent market share in major European countries
13 Nov 2021 //
NEWSNOW
Celltrion’s Monoclonal Antibody Treatment regdanvimab, Approved by theEU
13 Nov 2021 //
BUSINESSWIRE
COVID-19: EMA recommends authorisation of two monoclonal antibody medicines
11 Nov 2021 //
EMA
Celltrion begins ph1 clinical trial of inhalable COVID treatment in Australia
22 Oct 2021 //
KOREAHERALD
Celltrion applies for product approval for Avastin biosimilar in EU
12 Oct 2021 //
KOREABIOMED
Takeda, Moderna and more—Fierce Pharma Asia
08 Oct 2021 //
FIERCEPHARMA
EMA receives application for marketing authorisation for Regkirona
04 Oct 2021 //
EMA
EMA receives application for marketing authorisation for Regkirona
04 Oct 2021 //
EMA
U.S. to pay $1.2 billion for Abbott, Celltrion COVID tests
21 Sep 2021 //
BLOOMBERG
Celltrion Healthcare and 180 Life Sciences Enter Into MOU for a Supply Agreement
20 Sep 2021 //
GLOBENEWSWIRE
Celltrion`s MAb, CT-P59 is the 1st COVID-19 treatment approved by Korean MFDS
20 Sep 2021 //
BUSINESSWIRE
South Korea approves Celltrion`s COVID-19 treatment for use
16 Sep 2021 //
REUTERS
